M.Pharmacy course and syllabus

The Master of Pharmacy (M.Pharm/MPharm) is a postgraduate academic degree, typically spanning two years, focusing on advanced pharmaceutical education and research. It is designed to provide specialized knowledge in areas such as pharmacology, pharmaceutics, pharmaceutical chemistry, and pharmacy practice, often following a BPharm degree. 

Key Details about the Master of Pharmacy:

• Purpose: Prepares students for advanced roles in the pharmaceutical industry, research, and academia.
• Structure: Usually two years, combining coursework, practical laboratory training, and often a research thesis.
• Specializations: Common specializations include Pharmaceutical Chemistry, Pharmaceutics, Pharmacology, Pharmacognosy, and Pharmaceutical Analysis.
• Prerequisites: A Bachelor of Pharmacy (BPharm) degree is generally required for admission.
• Regional Differences: In some countries, it is a postgraduate degree (e.g., India), while in others, an "MPharm" can be an integrated undergraduate master's degree.
• Entrance Exams: In India, admission to many MPharm programs is based on the Graduate Pharmacy Aptitude Test (GPAT). 

The curriculum often covers advanced drug delivery systems, quality assurance, drug regulation, and industrial pharmacy. 

M.Pharmacy course and syllabus was framed by VV University, Rajasthan uptill now.

In India, universities had started M. Pharmacy on 25 to 30 subjects.
Now, PCI has made it only on 12 subjects.
Also for every subject, intake has been set as 15 students. So that importance of Pharmacy remains intact.

Some of the M. Pharm subjects are :
Pharmaceutics
Pharmaceutical Chemistry
Regulatory Affairs
Pharmaceutical QA
Pharmacognosy
Pharmacology
Pharmacy Practice

Scope of taking specialization in M.Pharm

By taking specialization in any specific area while doing M.Pharm, one can focus to make a career in field like Pharmacology, Pharmaceutical Technology, Drug Discovery and Development. Another benefit of taking specialization is that aspirants can look for teaching jobs in both government and private pharmacy colleges.

M.Pharm in Quality Assurance course can help students opt for job of Quality Assurance Health Manager or Quality Control Manager in reputed firms like Cipla, Ranbaxy, Lupin Pharmaceuticals Limited etc. After completing this course, one can find the job of Quality Assurance Manager or Quality Control Executive in public sector undertakings like Bengal Chemicals and Pharmaceuticals Limited (BCPL), Rajasthan Drugs and Pharmaceuticals Ltd (RDPL) and Indian Drugs and Pharmaceuticals Limited (IDPL) too.

Those who possess M.Pharm in Pharmaceutical Chemistry/Pharmacognosy/ Medicinal Chemistry can join as Project Assistant in National Botanical Research Institute of CSIR. Remuneration offered for this post is Rs. 12,000 per month. After M.Pharm in Pharmaceutical Chemistry, one can pursue Ph.D in Pharmaceutical Chemistry and join Defence Research and Development Organization (DRDO) as Research Associate.

After completing M.Pharm in Clinical Pharmacy, one can work as Clinical Research Associate or Clinical Pharmacist in clinical research laboratories like Accutest Research Laboratories Private Limited. M.Pharm graduates in Drug Regulatory Affairs can find the job of Drug Regulatory Affairs Manager in companies like Novartis India Limited.

On successful completion of M.Pharm course in Pharmaceutics, Pharmacology and Pharmaceutical Marketing and Management, one can pursue Ph.D in corresponding stream and find the job of Research Associate in research institutes like National Institute of Pharmaceutical Education and Research (NIPER). After getting into the post of Research Associate in NIPER, one can earn a salary of Rs. 16,000 per month.

Source: http://entrance-exam.net/mpharm-specialization-areas-and-career-potential/#ixzz4m9hQJTgL


Those who want to pursue M.Pharm course can take specialization in streams like Pharmacology, Clinical Pharmacy, Quality Assurance, Industrial Pharmacy and Medicinal Chemistry. The advantage of doing specialization is that aspirants can pursue Ph.D in Pharmaceutics, Pharmacology and  Pharmaceutical Marketing and Management after M.Pharm course. There are also job opportunities available in public and private sector firms like Bengal Chemicals and Pharmaceuticals Limited (BCPL), National Botanical Research Institute (NBRI) and Indian Drugs and Pharmaceuticals Ltd (IDPL) for M.Pharm graduates.

Source: http://entrance-exam.net/mpharm-specialization-areas-and-career-potential/#ixzz4m9mGuns9
Other Subjects :

Specialization areas in M.Pharm

• M.Pharm in Biopharmaceutics
• M.Pharm in Drug Regulatory Affairs
• M.Pharm in Biotechnology
• M.Pharm in Pharmaceutical Chemistry
• M.Pharm in Medicinal Natural Products
• M.Pharm in Pharmaceutical Technology
• M.Pharm in Bulk Drugs
• M.Pharm in Pharmaceutical Analysis and Quality Assurance
• M.Pharm in Industrial Pharmacy
• M.Pharm in Clinical Pharmacy
• M.Pharm in Pharmaceutical Administration
• M.Pharm in Medicinal Chemistry
• M.Pharm in Drug Discovery and Development
• M.Pharm in Pharmaceutical Technology and Biopharmaceutics
• M.Pharm in Pharmaceutical Analysis
• M.Pharm in Pharmacology
• M.Pharm in Pharmaceutical Marketing Management
• M.Pharm in Phytopharmaceuticals and Natural products
• M.Pharm in Pharmaceutical Biotechnology
• M.Pharm in Quality Assurance
• M.Pharm in Pharmacognosy and Phytochemistry
• M.Pharm in Pharmacy Practice
• M.Pharm in Pharmaceutics

Source: http://entrance-exam.net/mpharm-specialization-areas-and-career-potential/#ixzz4m9hlaabX

PharmacyPractice-IndianContext

#PharmacyPractice-IndianContext

👉Pharmacy Practice has no definition.

👉Pharmacy Practice has not been recognised by the Law and the Government or Private administration.

👉 Health Sector has done away with Pharmacists with the Amendment of Sch K. (Thanks to PCI, IPA and Our Pharmacy Officers in DTAB)

👉 There is no specific License to Practice Pharmacy and No detailed protocol to Inspect, Verify, and to punish the violators.

👉 It is just a glorified name given by pharmacy people @PCI and @Academy to camouflage simple dispensing and selling of drugs.

POV: Bhagwan PS

Note : Then what about PPR 2015, and amendments ? 

#CanPharmacyPracticeBeARealityInIndia?

Let’s be honest about Pharmacy Practice in India.

🤔 Pharmacy Practice Regulations (PPR) 2015–25 are repeatedly cited as proof that pharmacy practice is legally recognized in India. 

❌In reality, that claim does not stand up to scrutiny. PPR 2015–25 were framed by the Pharmacy Council of India under the Pharmacy Act, 1948 to hoodwink PharmD students and Graduates.

☑️But the Pharmacy Act primarily governs education and registration. 

❌It does not confer enforceable patient-care authority, nor does it empower PCI to regulate clinical practice on the ground. 

❌Calling PPR a “regulation” does not automatically make it enforceable.

☑️On the field, real power lies with State Drug Control Departments under the Drugs and Cosmetics Act. 

☑️Licensing, inspections, prosecutions, and control over dispensing are all under FDA jurisdiction. 

❌PPR provisions are not embedded in State Drug Rules, and therefore remain legally optional.

❌FDAs are not bound to enforce what the law does not mandate.

☑️That is why pharmacy practice in India exists only in pockets. 

☑️A few hospitals run clinical pharmacy services because administrators allow it not the system.

☑️A few pharmacists counsel patients because they personally believe in it.

❌This is not system-driven practice;

 It is goodwill-driven survival.

☑️ The uncomfortable truth is this: 

• PPR 2015–25 is not legally tenable as an enforcement instrument. 

• It creates expectations without authority and 

(Like Alcohol, It creates desire but takes away performance..)

• It assigns responsibility without power. 

Worse,

• It gives the illusion of progress while shielding regulators from accountability for not securing supportive legislation.

👉 If pharmacy practice is truly the goal, then guidelines are not enough. 

👉 The profession needs statutory backing—A comprehensive

 "The Indian Pharmacy Practice Regulation Act".

👉 Fresh Rules have to be framed after the Act is put in place.

❌ Without that, PPR remains a document of intent, not law.

😢 Continuing to celebrate PPR while ignoring its legal weakness is intellectual dishonesty. (Bankruptcy) 

📢Pharmacy practice will not be built on aspirations, circulars, or seminars, Webinars of so called Resource Persons. 

👉It will be built only when law, administration, and accountability are aligned.

Till then, let’s stop pretending.🫢

#PCI, #PPR15-25,

#MinistryofHealthandFamilyWelfare 

#AIPDA 

#PharmD 

#APTI

POV: Bhagwan PS

In pharmaceutical world, types of patents:

Pharmaceutical patents protect various aspects of drug development, primarily categorized into product (active ingredients), process (manufacturing methods), formulation (dosage/delivery), and method-of-use (new applications) patents. These, along with polymorph, combination, and product-by-process patents, form "patent walls" to extend market exclusivity. 

Key Types of Pharmaceutical Patents

• Product Patents: Protect the active pharmaceutical ingredient (API) or chemical molecule itself, offering the strongest protection.
• Process/Manufacturing Patents: Protect the specific methods used to create the API or the final drug.
• Formulation/Composition Patents: Cover the specific mixture, dosage form (e.g., tablet, syrup), or inactive ingredients.
• Method-of-Use Patents: Protect new therapeutic uses for previously known drugs.
• Product-by-Process Patents: Define a product based on how it is manufactured.
• Polymorph Patents: Protect different crystalline structures of an existing drug compound.
• Combination Patents: Cover mixtures of two or more active ingredients.
• Markush Claims: Broad claims covering a range of related chemical compounds.
• Design Patents: Protect the unique, ornamental design of packaging or delivery devices like inhalers. 

Other Forms of Exclusivity

• New Chemical Entity (NCE) Exclusivity: FDA provides 5 years of market protection for new active ingredients.
• Orphan Drug Exclusivity: 7 years for drugs treating rare diseases.
• Pediatric Exclusivity: A 6-month extension granted for conducting pediatric studies. 

Common Patenting Strategies
Pharmaceutical companies often use "evergreening" tactics, filing multiple patents for a single drug—such as for new formulations or dosages—to extend protection beyond the initial 20-year term of the main product patent.